宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02659 宝济药业-B

未开盘 04-27 16:08:28

82.150

+4.300

+5.52%

最高89.700	最低52.250	成交量427.11万
今开77.950	昨收77.850	日振幅48.11%
总市值267.79亿	流通市值126.51亿	总股本3.26亿
成交额3.06亿	换手率2.77%	流通股本1.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":82.15,"timestamp":1777277308745,"preClose":77.85,"halted":0,"volume":4271130,"delay":0,"changeRate":0.05523442517662186,"floatShares":154000000,"shares":325981465,"eps":-1.5615572691367314,"marketStatus":"未开盘","change":4.3,"latestTime":"04-27 16:08:28","open":77.95,"high":89.7,"low":52.25,"amount":306100870,"amplitude":0.481053,"askPrice":84.2,"askSize":4700,"bidPrice":82.15,"bidSize":1100,"shortable":0,"etf":0,"ttmEps":-1.5420378032725222,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":0,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":77.85,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"volumeRatio":7.3734501713163905,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02659","defaultTab":"news","newsList":[{"id":"1103101923","title":"宝济药业-B：2025年主营业务快速推进，收入显著增长并强化研发与资本实力","url":"https://stock-news.laohu8.com/highlight/detail?id=1103101923","media":"公告速递","labels":["dataReport","SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103101923?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:09","pubTimestamp":1777288199,"startTime":"0","endTime":"0","summary":"宝济药业-B是一家专注合成生物技术的生物医药企业，核心布局在自身免疫性疾病、大容量皮下给药、辅助生殖及重组生物制剂等领域。截至2025年，公司持续推进12款自主研发药物管线，其中KJ017、KJ103及SJ02为核心候选产品。总体而言，2025年对宝济药业-B具有里程碑意义：一方面，公司在核心产品推广、全球化布局与新产品研发上均取得扎实进展；另一方面，上市为其进一步拓展资金与资源打开新局面。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B：2025年主营业务快速推进，收入显著增长并强化研发与资本实力","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179144809","title":"异动解读 | 产品获批及临床试验受理，宝济药业-B盘中大涨11.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179144809","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179144809?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:20","pubTimestamp":1777274442,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨11.95%，引起了市场的广泛关注。消息面上，宝济药业自主研发的重组乌司他丁（BJ044）临床试验申请已正式获得国家药品监督管理局受理，该产品与公司另一重点产品重组人糜蛋白酶KJ101的临床进展形成了明确的战略协同。此外，公司核心品种注射用人玻璃酸酶（葆舒宜®）已正式获得国家药监局批准上市。西牛证券此前指出，公司产品于中国具有先发优势，预计相关产品将于2026年开始为公司带来显著的收入贡献，这增强了市场对公司未来业绩增长的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629702540","title":"从Biotech到18A板块“底层运营商”，宝济药业-B（02659）如何扼守千亿市场的“入场券”","url":"https://stock-news.laohu8.com/highlight/detail?id=2629702540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629702540?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:54","pubTimestamp":1776909264,"startTime":"0","endTime":"0","summary":"在港股18A生物医药板块步入“价值回归”的2026年，一场关于“生物制造工业化”与“给药场景革命”的深刻范式转移正在悄然发生。在这一宏大的行业叙事中，宝济药业-B正另辟蹊径，凭借其独特的合成生物学底座与“场景驱动”战略，从一家传统的Biotech公司进化为中国生物医药产业升级的关键“连接器”。当前，宝济药业在上海、江苏等地布局近10万平方米生产基地、2.6万升反应器容积并配备超过70%的研发人员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","XBI","BK1161","02659","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275533","title":"宝济药业(02659)重组乌司他丁(BJ044)IND申请获受理，开启重组蛋白药物新纪元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275533","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628275533?lang=zh_cn&edition=full","pubTime":"2026-04-17 15:29","pubTimestamp":1776410984,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，宝济药业宣布，公司自主研发的重组乌司他丁临床试验申请已正式获得国家药品监督管理局受理。数据显示，2023年中国乌司他丁市场规模约为11.6亿元。战略协同：重组技术平台的双轮驱动BJ044的IND受理，与公司另一重点产品重组人糜蛋白酶KJ101的临床进展形成了明确的战略协同。总体而言，BJ044的IND受理不仅是单一产品的进展，更代表了一种具有长期战略价值的技术方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","IND","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627269858","title":"静脉转皮下的革命已至，KJ017正式获批，宝济药业（02659）正成为大分子药物生态的“枢纽核心”","url":"https://stock-news.laohu8.com/highlight/detail?id=2627269858","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627269858?lang=zh_cn&edition=full","pubTime":"2026-04-16 13:36","pubTimestamp":1776317819,"startTime":"0","endTime":"0","summary":"在生物医药“去静脉化”革命浪潮已至的当下，KJ017的正式入场，究竟将如何撬动宝济药业乃至整个皮下给药市场的估值天花板？随着2025年财报中营收数据的首次呈现以及2026年KJ017放量预期的增强，宝济药业有望迎来估值与股价的双重“戴维斯双击”。此次KJ017的获批，将成为宝济药业在港股市场实现价值重构的催化剂，而SJ02与KJ017的协同并进，则为港股生物医药板块树立了一个从技术驱动向场景驱动、从融资驱动向业绩驱动成功转型的可持续增长样本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"静脉转皮下的革命已至，KJ017正式获批，宝济药业（02659）正成为大分子药物生态的“枢纽核心”","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139688800","title":"异动解读 | 核心产品KJ017获批上市，宝济药业-B盘中大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139688800","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139688800?lang=zh_cn&edition=full","pubTime":"2026-04-09 13:58","pubTimestamp":1775714297,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅拉升，涨幅达到5.02%，引起市场关注。消息面上，公司自主研发的注射用人玻璃酸酶（项目代号KJ017，商品名：葆舒宜®）已获得国家药品监督管理局批准上市，用于辅助皮下输液。该产品作为高度糖基化的重组人玻璃酸酶，能安全、快速地实现大容量皮下给药，解决了静脉通路困难患者的临床难题，其获批标志着公司核心管线取得重要商业化进展。分析指出，KJ017采用基因重组技术，相比传统动物源性产品具有更高的安全性和质量一致性，且在国内市场中进展领先。随着该产品上市，宝济药业有望填补市场空白，并凭借先发优势分享快速增长的国内重组人透明质酸酶市场，这增强了投资者对公司未来盈利能力的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626390318","title":"瞄准生物制药“卡脖子”难题，宝济药业(02659)给出技术驱动高质量发展答案","url":"https://stock-news.laohu8.com/highlight/detail?id=2626390318","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626390318?lang=zh_cn&edition=full","pubTime":"2026-04-09 13:35","pubTimestamp":1775712943,"startTime":"0","endTime":"0","summary":"02 生物制品利好政策纷至沓来，宝济药业致力于填补市场未被满足的需求，解决“卡脖子”风险近年，我国将关键生物制品自主可控视为国家竞争力的一部分，宝济药业主营的生物制药利好政策不断。如此来看，宝济药业KJ107的布局极具战略意义。目前国内市场中，宝济药业的重组人透明质酸酶进展最快，KJ017已获得国家药监局的NDA批准，预计上半年获批上市。KJ103抗GBM病适应症预计2026年上半年启动III期临床。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625991184","title":"宝济药业-B(02659)：注射用人玻璃酸酶获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2625991184","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625991184?lang=zh_cn&edition=full","pubTime":"2026-04-08 12:04","pubTimestamp":1775621079,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，于2026年3月31日，公司自主研发、中国领先的注射用人玻璃酸酶，规格为385U╱瓶，已获国家药品监督管理局批准上市，用于辅助皮下输液。KJ017是一种高度糖基化的重组人玻璃酸酶，能特异性分解皮下组织中的透明质酸，暂时性、局部性增加皮下组织细胞外基质的通透性，从而实现安全、快速、大容量皮下给药，为解决静脉通路困难患者的给药难题提供新选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141456919","title":"宝济药业-B3月股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1141456919","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141456919?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:50","pubTimestamp":1775119809,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年4月2日发布截至2026年3月31日的证券变动月报表，披露本期内股本结构及股份变动情况。根据公告，普通股H股类别本月底已发行股份数为154,327,250股，面值为每股人民币0.2元；普通股内资股类别本月底已发行股份数为171,654,215股，面值同为每股人民币0.2元。本月底法定注册股本总额人民币65,196,293元，与上月末持平。截至本月底，公司股本保持稳定。该份月报表由执行董事刘彦君签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624933865","title":"港股异动 | 宝济药业-B(02659)尾盘涨超8% SJ02已开启商业化进程 KJ103预计上半年提交NDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2624933865","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624933865?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:40","pubTimestamp":1775029250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B尾盘涨超8%，截至发稿，涨6.57%，报97.3港元，成交额8453.05万港元。消息面上，宝济药业此前发布全年业绩。其中，晟诺娃于2025年11月完成首批订单交付，全面开启商业化进程。值得注意的是，宝济药业另一款核心产品KJ103则展现了宝济在解决临床急需方面的爆发力。针对肾脏移植前脱敏这一医学难题，公司在2025年8月启动了III期试验，并已于2026年3月完成，预计2026年上半年向监管部门提交NDA申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161","VXUS","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107635046","title":"宝济药业-B拟选举刘彦军、王政、李翠为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1107635046","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107635046?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:42","pubTimestamp":1774514562,"startTime":"0","endTime":"0","summary":"宝济药业-B近日宣布，公司计划选举刘彦军、王政及李翠担任执行董事职务。此次人事变动旨在优化公司治理结构，提升管理团队的决策效率与专业能力。\n刘彦军、王政和李翠均在医药行业拥有丰富的从业经验，他们的加入有望为宝济药业-B的战略发展注入新的活力。公司表示，这一举措将进一步加强董事会职能，推动业务持续稳健增长。\n市场观察人士指出，执行董事的调整可能影响公司未来的业务方向与资本市场表现。投资者将密切关注新团队上任后的具体举措及业绩反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622227837","title":"宝济药业(02659)2025年度业绩：核心管线快速推进，SJ02完成首批订单交付","url":"https://stock-news.laohu8.com/highlight/detail?id=2622227837","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622227837?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:31","pubTimestamp":1774513868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业 公布了截至2025年12月31日止年度的全年业绩。报告期内，公司实现总营收0.49亿人民币，并在研发上持续投入以构建产品的核心竞争力，研发费用达2.48亿人民币。公司三款核心产品分别完成注册、临床和商业化的快速推进。其中，晟诺娃于2025年11月完成首批订单交付，全面开启商业化进程。2026年，公司的主要目标是继续推进多元化的临床产品组合，挖掘产品的临床和商业价值，并在KJ017 NDA获批后实现商业化上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622041766","title":"宝济药业-B(02659)：KJ103用于肾移植脱敏治疗III期临床试验随访完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2622041766","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622041766?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:22","pubTimestamp":1774416121,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，KJ103作为脱敏疗法用于中国等待肾脏移植的高敏感患者的III期临床试验，已于2026年3月20日完成所有入组受试者的主要试验随访。于2025年8月，公司启动了KJ103用于高度致敏肾移植患者脱敏治疗的III期临床试验，旨在有效清除预存的HLA抗体并预防超急性排斥反应。于2024年11月，公司就KJ103的该适应症获得了国家药监局对KJ103的突破性治疗药物认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK4134","BK1161","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618190458","title":"宝济药业-B(02659)：KJ101新增适应症获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618190458","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618190458?lang=zh_cn&edition=full","pubTime":"2026-03-12 12:19","pubTimestamp":1773289175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，公司自主研发、中国领先的经由合成生物学开发的重组人糜蛋白酶KJ101，已获中国国家药监局批准，可在中国开展用于胃镜检查时溶解去除胃内黏液的临床试验。KJ101具有纯度高、无动物源病毒污染的风险及无致敏性等核心优势。针对烧伤、外伤、手术切口、压力性溃疡及糖尿病足溃疡等伤口愈合适应症，该公司已于2025年2月获得国家药监局对KJ101的IND批准，并于2025年7月启动了其II期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195288141","title":"宝济药业-B：国家药监局批准KJ101在中国开展胃黏液清除临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1195288141","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195288141?lang=zh_cn&edition=full","pubTime":"2026-03-12 12:03","pubTimestamp":1773288218,"startTime":"0","endTime":"0","summary":"宝济药业-B宣布，其研发的创新药KJ101已获得中国国家药品监督管理局（NMPA）的临床试验批准，将在中国开展针对胃黏液清除的临床研究。这一进展标志着公司在消化系统疾病治疗领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617673630","title":"宝济药业-B03月06日主力净流出2077.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2617673630","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617673630?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:15","pubTimestamp":1772784940,"startTime":"0","endTime":"0","summary":"03月06日, 宝济药业-B股价跌36.63%，报收101.40元，成交金额1.2亿元，换手率0.60%，振幅39.63%，量比1.14。宝济药业-B今日主力资金净流出2077.3万元，上一交易日主力净流入2491.8万元。该股近5个交易日下跌34.54%，主力资金累计净流入1517.2万元；近20日主力资金累计净流入4.7亿元，其中净流入天数为12日。该股主力净额占比0.13%，港股市场排名2686/2717。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161824a4534a42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161824a4534a42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616320203","title":"宝济药业-B03月03日主力净流入1289.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2616320203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616320203?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:16","pubTimestamp":1772525765,"startTime":"0","endTime":"0","summary":"03月03日, 宝济药业-B股价涨4.89%，报收154.40元，成交金额1.2亿元，换手率0.54%，振幅17.87%，量比0.99。宝济药业-B今日主力资金净流入1289.8万元，上一交易日主力净流出257.8万元。该股近5个交易日下跌23.16%，主力资金累计净流入4548.0万元；近20日主力资金累计净流入4.6亿元，其中净流入天数为10日。该股主力净额占比0.05%，港股市场排名112/2719。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162215a445bd53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162215a445bd53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616847333","title":"宝济药业-B03月02日遭主力抛售257.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616847333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616847333?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:15","pubTimestamp":1772439331,"startTime":"0","endTime":"0","summary":"03月02日, 宝济药业-B股价跌4.97%，报收147.20元，成交金额1.0亿元，换手率0.45%，振幅22.14%，量比0.85。宝济药业-B今日主力资金净流出257.8万元，连续3日净流出，上一交易日主力净流出947.9万元。该股近5个交易日下跌19.37%，主力资金累计净流入1.6亿元；近20日主力资金累计净流入4.5亿元，其中净流入天数为10日。该股主力净额占比0.01%，港股市场排名2372/2720。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302161749a730afa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302161749a730afa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614792072","title":"宝济药业-B02月26日主力净流出1742.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2614792072","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614792072?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:15","pubTimestamp":1772093751,"startTime":"0","endTime":"0","summary":"02月26日, 宝济药业-B股价跌8.13%，报收182.00元，成交金额1.8亿元，换手率0.62%，振幅17.11%，量比0.91。宝济药业-B今日主力资金净流出1742.1万元，上一交易日主力净流入6206.1万元。该股近5个交易日上涨7.82%，主力资金累计净流入2.5亿元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入4.6亿元，其中净流入天数为10日。该股主力净额占比0.06%，港股市场排名2590/2718。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162029a4caa4e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162029a4caa4e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614365729","title":"宝济药业-B02月24日获主力大幅加仓1.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614365729","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614365729?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:15","pubTimestamp":1771920930,"startTime":"0","endTime":"0","summary":"02月24日, 宝济药业-B股价涨11.61%，报收199.90元，成交金额2.3亿元，换手率0.76%，振幅11.67%，量比1.05。宝济药业-B今日主力资金净流入1.3亿元，连续5日净流入，上一交易日主力净流入466.7万元。该股近5个交易日上涨34.27%，主力资金累计净流入4.2亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4.1亿元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161713a4c22268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161713a4c22268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baopharma.com","stockEarnings":[{"period":"1week","weight":-0.0872},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.1874},{"period":"6month","weight":2.1141},{"period":"ytd","weight":0.0593}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.016},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0115}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海宝济药业股份有限公司专注于重组蛋白药物和抗体药物的产业化与商业化。我们在上海建设了符合cGMP标准的生产基地，占地约63,000平方米，规划了多条覆盖哺乳动物细胞表达系统及大肠杆菌/酵母表达系统的原液生产线，以及水针剂、冻干粉针剂和一次性预灌封制剂的成品生产线。","exchange":"SEHK","name":"宝济药业-B","nameEN":"BAO PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宝济药业-B,02659,宝济药业-B股票,宝济药业-B股票老虎,宝济药业-B股票老虎国际,宝济药业-B行情,宝济药业-B股票行情,宝济药业-B股价,宝济药业-B股市,宝济药业-B股票价格,宝济药业-B股票交易,宝济药业-B股票购买,宝济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}